Inhibikase Therapeutics, Inc. (IKT) has a market capitalization of $120.71M and trades at $1.70. The 52-week range is 1.33-2.365.
Key metrics include a trailing Price-to-Earnings (P/E) ratio of -3.5, Earnings Per Share (EPS) of $-0.49.
The stock has a beta of 0.86, operates in the Healthcare sector.
